Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 13/20 | 0.41 |
| ▸ | BCHE | P06276 | 5/20 | 0.41 |
| ▸ | ACHE | P22303 | 5/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13639088 | 1.00 | HTR2A (0.43) | HTR2ACHRM2BCHEACHECHRM4 | |
| SCHEMBL11348933 | 0.83 | HTR2A (0.47) | HTR2A | |
| SCHEMBL13636307 | 0.83 | MEN1 (0.44) | HTR2AMEN1KMT2ATDP1 | |
| SCHEMBL13636313 | 0.83 | MEN1 (0.44) | HTR2AMEN1KMT2ATDP1 | |
| SCHEMBL27935806 | 0.81 | HTR2A (0.41) | HTR2AMEN1KMT2A | |
| SCHEMBL10961574 | 0.81 | GABRA1 (0.46) | HTR2AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL24797465 | 0.80 | HTR2A (0.47) | HTR2ACHRM2BCHEACHECHRM4 | |
| SCHEMBL13639096 | 0.80 | TACR1 (0.37) | HTR2ABCHEACHERECQLMEN1 | |
| SCHEMBL13639117 | 0.80 | TACR1 (0.37) | HTR2ABCHEACHERECQLMEN1 | |
| SCHEMBL13639086 | 0.77 | CNR1 (0.36) | HTR2AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304385-B2 | Macrocyclic tetrazolyl hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20090142299-A1 | MACROCYCLIC TETRAZOLYL HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090142299-A1 | MACROCYCLIC TETRAZOLYL HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS4, PRSS1, SPINT2 | HTR2A 3343/4885CHRM2 4872/4885BCHE 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.